S Pignata, D Califano, D Lorusso, L Arenare, M Bartoletti, U De Giorgi, C Andreetta, C Pisano, G Scambia, D Lombardi, A Farolfi, S Cinieri, A Passarelli, V Salutari, C De Angelis, C Mignogna, D Priolo, E D Capoluongo, S Tamberi, G L Scaglione, V Arcangeli, R De Cecio, G Scognamiglio, F Greco, A Spina, M Turinetto, D Russo, V Carbone, C Casartelli, C Schettino, F Perrone
BACKGROUND: Immunotherapy combined with chemotherapy significantly improves progression-free survival compared to first-line chemotherapy alone in advanced endometrial cancer, with a much larger effect size in microsatellite-instability high (MSI-H) cases. New biomarkers might help to select patients that may have benefit among those with a microsatellite-stable (MSS) tumor. METHODS: In a pre-planned translational analysis of the MITO END-3 trial, we assessed the significance of genomic abnormalities in patients randomized to standard carboplatin/paclitaxel without or with avelumab...
May 2, 2024: Annals of Oncology: Official Journal of the European Society for Medical Oncology